1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global HR+/HER2- Breast Cancer Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 CDK4/6 Inhibitors 1.2.3 PARP Inhibitors 1.2.4 PI3K Inhibitor 1.2.5 Others 1.3 Market by Application 1.3.1 Global HR+/HER2- Breast Cancer Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Hospitals 1.3.3 Cancer Center 1.3.4 Medical Research and Academic Institutions 1.3.5 Ambulatory Surgical Centers 1.3.6 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global HR+/HER2- Breast Cancer Market Perspective (2016-2027) 2.2 HR+/HER2- Breast Cancer Growth Trends by Regions 2.2.1 HR+/HER2- Breast Cancer Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 HR+/HER2- Breast Cancer Historic Market Share by Regions (2016-2021) 2.2.3 HR+/HER2- Breast Cancer Forecasted Market Size by Regions (2022-2027) 2.3 HR+/HER2- Breast Cancer Industry Dynamic 2.3.1 HR+/HER2- Breast Cancer Market Trends 2.3.2 HR+/HER2- Breast Cancer Market Drivers 2.3.3 HR+/HER2- Breast Cancer Market Challenges 2.3.4 HR+/HER2- Breast Cancer Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top HR+/HER2- Breast Cancer Players by Revenue 3.1.1 Global Top HR+/HER2- Breast Cancer Players by Revenue (2016-2021) 3.1.2 Global HR+/HER2- Breast Cancer Revenue Market Share by Players (2016-2021) 3.2 Global HR+/HER2- Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by HR+/HER2- Breast Cancer Revenue 3.4 Global HR+/HER2- Breast Cancer Market Concentration Ratio 3.4.1 Global HR+/HER2- Breast Cancer Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by HR+/HER2- Breast Cancer Revenue in 2020 3.5 HR+/HER2- Breast Cancer Key Players Head office and Area Served 3.6 Key Players HR+/HER2- Breast Cancer Product Solution and Service 3.7 Date of Enter into HR+/HER2- Breast Cancer Market 3.8 Mergers & Acquisitions, Expansion Plans 4 HR+/HER2- Breast Cancer Breakdown Data by Type 4.1 Global HR+/HER2- Breast Cancer Historic Market Size by Type (2016-2021) 4.2 Global HR+/HER2- Breast Cancer Forecasted Market Size by Type (2022-2027) 5 HR+/HER2- Breast Cancer Breakdown Data by Application 5.1 Global HR+/HER2- Breast Cancer Historic Market Size by Application (2016-2021) 5.2 Global HR+/HER2- Breast Cancer Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America HR+/HER2- Breast Cancer Market Size (2016-2027) 6.2 North America HR+/HER2- Breast Cancer Market Size by Type 6.2.1 North America HR+/HER2- Breast Cancer Market Size by Type (2016-2021) 6.2.2 North America HR+/HER2- Breast Cancer Market Size by Type (2022-2027) 6.2.3 North America HR+/HER2- Breast Cancer Market Size by Type (2016-2027) 6.3 North America HR+/HER2- Breast Cancer Market Size by Application 6.3.1 North America HR+/HER2- Breast Cancer Market Size by Application (2016-2021) 6.3.2 North America HR+/HER2- Breast Cancer Market Size by Application (2022-2027) 6.3.3 North America HR+/HER2- Breast Cancer Market Size by Application (2016-2027) 6.4 North America HR+/HER2- Breast Cancer Market Size by Country 6.4.1 North America HR+/HER2- Breast Cancer Market Size by Country (2016-2021) 6.4.2 North America HR+/HER2- Breast Cancer Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe HR+/HER2- Breast Cancer Market Size (2016-2027) 7.2 Europe HR+/HER2- Breast Cancer Market Size by Type 7.2.1 Europe HR+/HER2- Breast Cancer Market Size by Type (2016-2021) 7.2.2 Europe HR+/HER2- Breast Cancer Market Size by Type (2022-2027) 7.2.3 Europe HR+/HER2- Breast Cancer Market Size by Type (2016-2027) 7.3 Europe HR+/HER2- Breast Cancer Market Size by Application 7.3.1 Europe HR+/HER2- Breast Cancer Market Size by Application (2016-2021) 7.3.2 Europe HR+/HER2- Breast Cancer Market Size by Application (2022-2027) 7.3.3 Europe HR+/HER2- Breast Cancer Market Size by Application (2016-2027) 7.4 Europe HR+/HER2- Breast Cancer Market Size by Country 7.4.1 Europe HR+/HER2- Breast Cancer Market Size by Country (2016-2021) 7.4.2 Europe HR+/HER2- Breast Cancer Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific HR+/HER2- Breast Cancer Market Size (2016-2027) 8.2 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Type 8.2.1 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Type (2016-2021) 8.2.2 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Type (2022-2027) 8.2.3 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Type (2016-2027) 8.3 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Application 8.3.1 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Application (2016-2021) 8.3.2 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Application (2022-2027) 8.3.3 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Application (2016-2027) 8.4 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Region 8.4.1 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Region (2016-2021) 8.4.2 Asia-Pacific HR+/HER2- Breast Cancer Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America HR+/HER2- Breast Cancer Market Size (2016-2027) 9.2 Latin America HR+/HER2- Breast Cancer Market Size by Type 9.2.1 Latin America HR+/HER2- Breast Cancer Market Size by Type (2016-2021) 9.2.2 Latin America HR+/HER2- Breast Cancer Market Size by Type (2022-2027) 9.2.3 Latin America HR+/HER2- Breast Cancer Market Size by Type (2016-2027) 9.3 Latin America HR+/HER2- Breast Cancer Market Size by Application 9.3.1 Latin America HR+/HER2- Breast Cancer Market Size by Application (2016-2021) 9.3.2 Latin America HR+/HER2- Breast Cancer Market Size by Application (2022-2027) 9.3.3 Latin America HR+/HER2- Breast Cancer Market Size by Application (2016-2027) 9.4 Latin America HR+/HER2- Breast Cancer Market Size by Country 9.4.1 Latin America HR+/HER2- Breast Cancer Market Size by Country (2016-2021) 9.4.2 Latin America HR+/HER2- Breast Cancer Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa HR+/HER2- Breast Cancer Market Size (2016-2027) 10.2 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Type 10.2.1 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Type (2016-2021) 10.2.2 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Type (2022-2027) 10.2.3 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Type (2016-2027) 10.3 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Application 10.3.1 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Application (2016-2021) 10.3.2 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Application (2022-2027) 10.3.3 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Application (2016-2027) 10.4 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Country 10.4.1 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Country (2016-2021) 10.4.2 Middle East & Africa HR+/HER2- Breast Cancer Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Jiangsu HengRui Medicine 11.1.1 Jiangsu HengRui Medicine Company Details 11.1.2 Jiangsu HengRui Medicine Business Overview 11.1.3 Jiangsu HengRui Medicine HR+/HER2- Breast Cancer Introduction 11.1.4 Jiangsu HengRui Medicine Revenue in HR+/HER2- Breast Cancer Business (2016-2021) 11.1.5 Jiangsu HengRui Medicine Recent Development 11.2 Odonate Therapeutics 11.2.1 Odonate Therapeutics Company Details 11.2.2 Odonate Therapeutics Business Overview 11.2.3 Odonate Therapeutics HR+/HER2- Breast Cancer Introduction 11.2.4 Odonate Therapeutics Revenue in HR+/HER2- Breast Cancer Business (2016-2021) 11.2.5 Odonate Therapeutics Recent Development 11.3 Radius Pharmaceuticals 11.3.1 Radius Pharmaceuticals Company Details 11.3.2 Radius Pharmaceuticals Business Overview 11.3.3 Radius Pharmaceuticals HR+/HER2- Breast Cancer Introduction 11.3.4 Radius Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) 11.3.5 Radius Pharmaceuticals Recent Development 11.4 Immunomedics 11.4.1 Immunomedics Company Details 11.4.2 Immunomedics Business Overview 11.4.3 Immunomedics HR+/HER2- Breast Cancer Introduction 11.4.4 Immunomedics Revenue in HR+/HER2- Breast Cancer Business (2016-2021) 11.4.5 Immunomedics Recent Development 11.5 Roche Group 11.5.1 Roche Group Company Details 11.5.2 Roche Group Business Overview 11.5.3 Roche Group HR+/HER2- Breast Cancer Introduction 11.5.4 Roche Group Revenue in HR+/HER2- Breast Cancer Business (2016-2021) 11.5.5 Roche Group Recent Development 11.6 Syndax Pharmaceuticals 11.6.1 Syndax Pharmaceuticals Company Details 11.6.2 Syndax Pharmaceuticals Business Overview 11.6.3 Syndax Pharmaceuticals HR+/HER2- Breast Cancer Introduction 11.6.4 Syndax Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) 11.6.5 Syndax Pharmaceuticals Recent Development 11.7 Merck 11.7.1 Merck Company Details 11.7.2 Merck Business Overview 11.7.3 Merck HR+/HER2- Breast Cancer Introduction 11.7.4 Merck Revenue in HR+/HER2- Breast Cancer Business (2016-2021) 11.7.5 Merck Recent Development 11.8 Eagle Pharmaceuticals 11.8.1 Eagle Pharmaceuticals Company Details 11.8.2 Eagle Pharmaceuticals Business Overview 11.8.3 Eagle Pharmaceuticals HR+/HER2- Breast Cancer Introduction 11.8.4 Eagle Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) 11.8.5 Eagle Pharmaceuticals Recent Development 11.9 Merrimack Pharmaceuticals 11.9.1 Merrimack Pharmaceuticals Company Details 11.9.2 Merrimack Pharmaceuticals Business Overview 11.9.3 Merrimack Pharmaceuticals HR+/HER2- Breast Cancer Introduction 11.9.4 Merrimack Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) 11.9.5 Merrimack Pharmaceuticals Recent Development 11.10 GlaxoSmithKline 11.10.1 GlaxoSmithKline Company Details 11.10.2 GlaxoSmithKline Business Overview 11.10.3 GlaxoSmithKline HR+/HER2- Breast Cancer Introduction 11.10.4 GlaxoSmithKline Revenue in HR+/HER2- Breast Cancer Business (2016-2021) 11.10.5 GlaxoSmithKline Recent Development 11.11 Millennium Pharmaceuticals 11.11.1 Millennium Pharmaceuticals Company Details 11.11.2 Millennium Pharmaceuticals Business Overview 11.11.3 Millennium Pharmaceuticals HR+/HER2- Breast Cancer Introduction 11.11.4 Millennium Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) 11.11.5 Millennium Pharmaceuticals Recent Development 11.12 Bayer 11.12.1 Bayer Company Details 11.12.2 Bayer Business Overview 11.12.3 Bayer HR+/HER2- Breast Cancer Introduction 11.12.4 Bayer Revenue in HR+/HER2- Breast Cancer Business (2016-2021) 11.12.5 Bayer Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global HR+/HER2- Breast Cancer Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of CDK4/6 Inhibitors Table 3. Key Players of PARP Inhibitors Table 4. Key Players of PI3K Inhibitor Table 5. Key Players of Others Table 6. Global HR+/HER2- Breast Cancer Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 7. Global HR+/HER2- Breast Cancer Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 8. Global HR+/HER2- Breast Cancer Market Size by Regions (2016-2021) & (US$ Million) Table 9. Global HR+/HER2- Breast Cancer Market Share by Regions (2016-2021) Table 10. Global HR+/HER2- Breast Cancer Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 11. Global HR+/HER2- Breast Cancer Market Share by Regions (2022-2027) Table 12. HR+/HER2- Breast Cancer Market Trends Table 13. HR+/HER2- Breast Cancer Market Drivers Table 14. HR+/HER2- Breast Cancer Market Challenges Table 15. HR+/HER2- Breast Cancer Market Restraints Table 16. Global HR+/HER2- Breast Cancer Revenue by Players (2016-2021) & (US$ Million) Table 17. Global HR+/HER2- Breast Cancer Market Share by Players (2016-2021) Table 18. Global Top HR+/HER2- Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HR+/HER2- Breast Cancer as of 2020) Table 19. Ranking of Global Top HR+/HER2- Breast Cancer Companies by Revenue (US$ Million) in 2020 Table 20. Global 5 Largest Players Market Share by HR+/HER2- Breast Cancer Revenue (CR5 and HHI) & (2016-2021) Table 21. Key Players Headquarters and Area Served Table 22. Key Players HR+/HER2- Breast Cancer Product Solution and Service Table 23. Date of Enter into HR+/HER2- Breast Cancer Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global HR+/HER2- Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 26. Global HR+/HER2- Breast Cancer Revenue Market Share by Type (2016-2021) Table 27. Global HR+/HER2- Breast Cancer Forecasted Market Size by Type (2022-2027) (US$ Million) Table 28. Global HR+/HER2- Breast Cancer Revenue Market Share by Type (2022-2027) & (US$ Million) Table 29. Global HR+/HER2- Breast Cancer Market Size Share by Application (2016-2021) & (US$ Million) Table 30. Global HR+/HER2- Breast Cancer Revenue Market Share by Application (2016-2021) Table 31. Global HR+/HER2- Breast Cancer Forecasted Market Size by Application (2022-2027) (US$ Million) Table 32. Global HR+/HER2- Breast Cancer Revenue Market Share by Application (2022-2027) & (US$ Million) Table 33. North America HR+/HER2- Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 34. North America HR+/HER2- Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 35. North America HR+/HER2- Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 36. North America HR+/HER2- Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 37. North America HR+/HER2- Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 38. North America HR+/HER2- Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 39. Europe HR+/HER2- Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 40. Europe HR+/HER2- Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 41. Europe HR+/HER2- Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 42. Europe HR+/HER2- Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 43. Europe HR+/HER2- Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 44. Europe HR+/HER2- Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 45. Asia-Pacific HR+/HER2- Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 46. Asia-Pacific HR+/HER2- Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 47. Asia-Pacific HR+/HER2- Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 48. Asia-Pacific HR+/HER2- Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 49. Asia-Pacific HR+/HER2- Breast Cancer Market Size by Region (2016-2021) & (US$ Million) Table 50. Asia-Pacific HR+/HER2- Breast Cancer Market Size by Region (2022-2027) & (US$ Million) Table 51. Latin America HR+/HER2- Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 52. Latin America HR+/HER2- Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 53. Latin America HR+/HER2- Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 54. Latin America HR+/HER2- Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 55. Latin America HR+/HER2- Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 56. Latin America HR+/HER2- Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 57. Middle East & Africa HR+/HER2- Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 58. Middle East & Africa HR+/HER2- Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 59. Middle East & Africa HR+/HER2- Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 60. Middle East & Africa HR+/HER2- Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 61. Middle East & Africa HR+/HER2- Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 62. Middle East & Africa HR+/HER2- Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 63. Jiangsu HengRui Medicine Company Details Table 64. Jiangsu HengRui Medicine Business Overview Table 65. Jiangsu HengRui Medicine HR+/HER2- Breast Cancer Product Table 66. Jiangsu HengRui Medicine Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million) Table 67. Jiangsu HengRui Medicine Recent Development Table 68. Odonate Therapeutics Company Details Table 69. Odonate Therapeutics Business Overview Table 70. Odonate Therapeutics HR+/HER2- Breast Cancer Product Table 71. Odonate Therapeutics Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million) Table 72. Odonate Therapeutics Recent Development Table 73. Radius Pharmaceuticals Company Details Table 74. Radius Pharmaceuticals Business Overview Table 75. Radius Pharmaceuticals HR+/HER2- Breast Cancer Product Table 76. Radius Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million) Table 77. Radius Pharmaceuticals Recent Development Table 78. Immunomedics Company Details Table 79. Immunomedics Business Overview Table 80. Immunomedics HR+/HER2- Breast Cancer Product Table 81. Immunomedics Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million) Table 82. Immunomedics Recent Development Table 83. Roche Group Company Details Table 84. Roche Group Business Overview Table 85. Roche Group HR+/HER2- Breast Cancer Product Table 86. Roche Group Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million) Table 87. Roche Group Recent Development Table 88. Syndax Pharmaceuticals Company Details Table 89. Syndax Pharmaceuticals Business Overview Table 90. Syndax Pharmaceuticals HR+/HER2- Breast Cancer Product Table 91. Syndax Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million) Table 92. Syndax Pharmaceuticals Recent Development Table 93. Merck Company Details Table 94. Merck Business Overview Table 95. Merck HR+/HER2- Breast Cancer Product Table 96. Merck Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million) Table 97. Merck Recent Development Table 98. Eagle Pharmaceuticals Company Details Table 99. Eagle Pharmaceuticals Business Overview Table 100. Eagle Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million) Table 101. Eagle Pharmaceuticals Recent Development Table 102. Merrimack Pharmaceuticals Company Details Table 103. Merrimack Pharmaceuticals Business Overview Table 104. Merrimack Pharmaceuticals HR+/HER2- Breast Cancer Product Table 105. Merrimack Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million) Table 106. Merrimack Pharmaceuticals Recent Development Table 107. GlaxoSmithKline Company Details Table 108. GlaxoSmithKline Business Overview Table 109. GlaxoSmithKline HR+/HER2- Breast Cancer Product Table 110. GlaxoSmithKline Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million) Table 111. GlaxoSmithKline Recent Development Table 112. Millennium Pharmaceuticals Company Details Table 113. Millennium Pharmaceuticals Business Overview Table 114. Millennium Pharmaceuticals HR+/HER2- Breast Cancer Product Table 115. Millennium Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million) Table 116. Millennium Pharmaceuticals Recent Development Table 117. Bayer Company Details Table 118. Bayer Business Overview Table 119. Bayer HR+/HER2- Breast Cancer Product Table 120. Bayer Revenue in HR+/HER2- Breast Cancer Business (2016-2021) & (US$ Million) Table 121. Bayer Recent Development Table 122. Research Programs/Design for This Report Table 123. Key Data Information from Secondary Sources Table 124. Key Data Information from Primary Sources List of Figures Figure 1. Global HR+/HER2- Breast Cancer Market Share by Type: 2020 VS 2027 Figure 2. CDK4/6 Inhibitors Features Figure 3. PARP Inhibitors Features Figure 4. PI3K Inhibitor Features Figure 5. Others Features Figure 6. Global HR+/HER2- Breast Cancer Market Share by Application: 2020 VS 2027 Figure 7. Hospitals Case Studies Figure 8. Cancer Center Case Studies Figure 9. Medical Research and Academic Institutions Case Studies Figure 10. Ambulatory Surgical Centers Case Studies Figure 11. Others Case Studies Figure 12. HR+/HER2- Breast Cancer Report Years Considered Figure 13. Global HR+/HER2- Breast Cancer Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 14. Global HR+/HER2- Breast Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 15. Global HR+/HER2- Breast Cancer Market Share by Regions: 2020 VS 2027 Figure 16. Global HR+/HER2- Breast Cancer Market Share by Regions (2022-2027) Figure 17. Global HR+/HER2- Breast Cancer Market Share by Players in 2020 Figure 18. Global Top HR+/HER2- Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HR+/HER2- Breast Cancer as of 2020 Figure 19. The Top 10 and 5 Players Market Share by HR+/HER2- Breast Cancer Revenue in 2020 Figure 20. Global HR+/HER2- Breast Cancer Revenue Market Share by Type (2016-2021) Figure 21. Global HR+/HER2- Breast Cancer Revenue Market Share by Type (2022-2027) Figure 22. North America HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 23. North America HR+/HER2- Breast Cancer Market Share by Type (2016-2027) Figure 24. North America HR+/HER2- Breast Cancer Market Share by Application (2016-2027) Figure 25. North America HR+/HER2- Breast Cancer Market Share by Country (2016-2027) Figure 26. United States HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 27. Canada HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 28. Europe HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 29. Europe HR+/HER2- Breast Cancer Market Share by Type (2016-2027) Figure 30. Europe HR+/HER2- Breast Cancer Market Share by Application (2016-2027) Figure 31. Europe HR+/HER2- Breast Cancer Market Share by Country (2016-2027) Figure 32. Germany HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. France HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. U.K. HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Italy HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Russia HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. Nordic HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Asia-Pacific HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Asia-Pacific HR+/HER2- Breast Cancer Market Share by Type (2016-2027) Figure 40. Asia-Pacific HR+/HER2- Breast Cancer Market Share by Application (2016-2027) Figure 41. Asia-Pacific HR+/HER2- Breast Cancer Market Share by Region (2016-2027) Figure 42. China HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. Japan HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. South Korea HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Southeast Asia HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. India HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. Australia HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. Latin America HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. Latin America HR+/HER2- Breast Cancer Market Share by Type (2016-2027) Figure 50. Latin America HR+/HER2- Breast Cancer Market Share by Application (2016-2027) Figure 51. Latin America HR+/HER2- Breast Cancer Market Share by Country (2016-2027) Figure 52. Mexico HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 53. Brazil HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 54. Middle East & Africa HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 55. Middle East & Africa HR+/HER2- Breast Cancer Market Share by Type (2016-2027) Figure 56. Middle East & Africa HR+/HER2- Breast Cancer Market Share by Application (2016-2027) Figure 57. Middle East & Africa HR+/HER2- Breast Cancer Market Share by Country (2016-2027) Figure 58. Turkey HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 59. Saudi Arabia HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 60. UAE HR+/HER2- Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 61. Jiangsu HengRui Medicine Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021) Figure 62. Odonate Therapeutics Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021) Figure 63. Radius Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021) Figure 64. Immunomedics Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021) Figure 65. Roche Group Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021) Figure 66. Syndax Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021) Figure 67. Merck Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021) Figure 68. Eagle Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021) Figure 69. Merrimack Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021) Figure 70. GlaxoSmithKline Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021) Figure 71. Millennium Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021) Figure 72. Bayer Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2016-2021) Figure 73. Bottom-up and Top-down Approaches for This Report Figure 74. Data Triangulation Figure 75. Key Executives Interviewed

Jiangsu HengRui Medicine Odonate Therapeutics Radius Pharmaceuticals Immunomedics Roche Group Syndax Pharmaceuticals Merck Eagle Pharmaceuticals Merrimack Pharmaceuticals GlaxoSmithKline Millennium Pharmaceuticals Bayer